{"id":576085,"date":"2023-07-14T00:00:00","date_gmt":"2023-07-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/trsqon0006-2023-biopharma-chronic-myeloid-leukemia-treatment-sequencing-us-2023\/"},"modified":"2026-03-31T10:32:32","modified_gmt":"2026-03-31T10:32:32","slug":"trsqon0006-2023-biopharma-chronic-myeloid-leukemia-treatment-sequencing-us-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/trsqon0006-2023-biopharma-chronic-myeloid-leukemia-treatment-sequencing-us-2023\/","title":{"rendered":"Chronic Myeloid Leukemia | Treatment Sequencing | US | 2023"},"content":{"rendered":"<p><strong>Key benefits and uses<\/strong><\/p>\n<ul>\n<li><strong>Pinpoint<\/strong> current drug positioning and uptake in one snapshot to facilitate forecasting<\/li>\n<li><strong>Drill down<\/strong> into physicians\u2019 treatment sequences and understand whom to position against or how to defend share<\/li>\n<li><strong>Identify<\/strong> untapped treatment scenarios and key competitors to aid trial design<\/li>\n<li><strong>Evaluate<\/strong> unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages<\/li>\n<li><strong>Discover<\/strong> untapped populations to expand product share and drive strategic decisions<\/li>\n<\/ul>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>Where is my product positioned versus competitors in the treatment journey?<\/li>\n<li>What are physicians\u2019 most frequent treatment sequences? Who is benefiting, and how can I defend my asset\u2019s share and position?<\/li>\n<li>What are the market-relevant treatment scenarios according to oncology experts?<\/li>\n<li>Where are the untapped business opportunities on which I can capitalize?<\/li>\n<li>How can I optimize trial design and ensure a competitive edge for my pipeline asset?<\/li>\n<\/ul>\n<p><strong>Geography<\/strong><\/p>\n<p>United States<\/p>\n<p><strong>Primary market research<\/strong><\/p>\n<p>Survey of 103 U.S. hematologist-oncologists<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p><em>Treatment Sequencing<\/em> provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and Clarivate oncology experts\u2019 assumptions.<\/p>\n","protected":false},"template":"","class_list":["post-576085","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-myeloid-leukemia","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576085\/revisions"}],"predecessor-version":[{"id":577533,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576085\/revisions\/577533"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=576085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}